Cargando…

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis

PURPOSE: High levels of tumor-infiltrating lymphocytes (TILs) are associated with better outcomes in early breast cancer and higher pathological response rates to neoadjuvant chemotherapy especially in the triple-negative (TNBC) and HER2+ subtypes. However, the dynamic changes in TILs levels after n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yajing, Tzoras, Evangelos, Matikas, Alexios, Bergh, Jonas, Valachis, Antonios, Zerdes, Ioannis, Foukakis, Theodoros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749788/ https://www.ncbi.nlm.nih.gov/pubmed/36531050 http://dx.doi.org/10.3389/fonc.2022.999843

Ejemplares similares

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
por: Rosin, Justus, et al.
Publicado: (2023)

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
por: Zhou, Qiong, et al.
Publicado: (2021)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS
por: Wang, Qiong, et al.
Publicado: (2020)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Prognostic value of systemic inflammation response index in hepatoblastoma patients receiving preoperative neoadjuvant chemotherapy
por: Zheng, Chen, et al.
Publicado: (2023)

Corrigendum: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS
por: Wang, Qiong, et al.
Publicado: (2021)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand
por: Intarawichian, Piyapharom, et al.
Publicado: (2022)

The Prognostic Impact of Combined Tumor-Infiltrating Lymphocytes and Pretreatment Blood Lymphocyte Percentage in Locally Advanced Nasopharyngeal Carcinoma
por: Cai, Zhuochen, et al.
Publicado: (2022)

Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma
por: Wongpattaraworakul, Wattawan, et al.
Publicado: (2022)

The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
por: Gao, Siming, et al.
Publicado: (2023)

Prognostic Value of Tumor-Infiltrating Lymphocytes Differs Depending on Lymphocyte Subsets in Esophageal Squamous Cell Carcinoma: An Updated Meta-Analysis
por: Hao, Jiatao, et al.
Publicado: (2020)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis
por: Paakkola, N.-M., et al.
Publicado: (2021)

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2019)

Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
por: Bellone, Matteo, et al.
Publicado: (2013)

Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
por: Qi, Xue, et al.
Publicado: (2023)

Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma
por: Lin, Zhi-qiang, et al.
Publicado: (2022)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Prognostic Evaluation of Metastasis-Related Lymphocyte/Monocyte Ratio in Stage Ⅰ-Ⅲ Breast Cancer Receiving Chemotherapy
por: Zhang, Zihan, et al.
Publicado: (2022)

Decreased CD8(+) Lymphocytic Infiltration in Multifocal and Multicentric Glioblastomas
por: Wang, Run, et al.
Publicado: (2021)

Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy
por: Zdanowski, Anna, et al.
Publicado: (2023)

Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis
por: Tian, Chunfang, et al.
Publicado: (2021)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34dqmd95cptgmkslt9jddvgeq6